
Paul Klein
Analyst
OBJECTIVE CORPORATION LIMITED: Buying pressure
Objective Corporation Limited shares have recently experienced an upward movement with a return of higher volumes and volatility. This technical chart pattern suggests a continuation of the upward movement.
August 21, 2025 at 03:47 am EDT
THE TRADE DESK, INC.: A long term support level to be taken advantage of
The Trade Desk, Inc. shares are sitting close to an important technical support area around 46.24 USD based on weekly price data. Against this backdrop, investors can use this good timing for new long positions.
August 18, 2025 at 11:18 am EDT
ERSTE BANK POLSKA S.A.: A reversal of the trend is being expected
Shares in Santander Bank Polska S.A. reflect a technical chart that has deteriorated, suggesting that the beginning of a tendency reversal is near, which could lead to a somewhat longer downward-trading phase.
August 13, 2025 at 10:34 am EDT
COVESTRO AG: Below a resistance on the weekly chart
Covestro AG shares are trading in close proximity to a major resistance zone estabished around 60.84 EUR on the weekly chart. The potential for additional upside seems limited, which suggests that short positions can be opened at this time.
August 13, 2025 at 10:33 am EDT
BNP PARIBAS: Good timing to anticipate the return of volatility
There has been very little movement in BNP Paribas's share price. This situation is bound to change. An exit on the upside out of the current trading range should go with a comeback in volatility. Therefore, the timing for new long positions seems good.
August 13, 2025 at 10:04 am EDT
ZOETIS INC.: Helped by a technical support level
The recent downward movement has sent Zoetis Inc. shares back to attractive levels situated around 144.41 USD. This zone could put an end to the downward movement and offers a good timing for new long positions.
August 04, 2025 at 09:47 am EDT

Sandoz sues Amgen in the US
Swiss pharmaceutical group Sandoz announced on Monday that it had filed an anti-competitive practices complaint against US-based Amgen, accusing it of blocking the market entry of biosimilar competitors to its blockbuster arthritis treatment Enbrel (etanercept).
April 14, 2025 at 10:32 am EDT
Discover our authors
Chief Editor
Journalist
Journalist
Analyst
Journalist
- Stock Market
- Our authors
- Paul Klein



















